Lifeward Ltd. · NASDAQ:LFWD
Lifeward — ReWalk Robotics — Investor Presentation (October 2023)
32 slides from Lifeward's investor presentation, Oct 13, 2023
Slide 1: ReWalk Robotics Investor Presentation October 2023
ReWalk Robotics Investor Presentation October 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements contained in t
Slide 3: Recovery After Neurological or Physical Injury and Disability
Recovery After Neurological or Physical Injury and Disability Confidential – ReWalk Robotics 2023 ReWalk Robotics Mission: To fundamentally improve the quality of life for individuals with physical or neurological injury and disability through innovative technologies that enable mobility and wellnes
Slide 4: Getting People Back to Doing What They Love
Neurologic and physical disease or injury, including spinal cord injury (“SCI”) or stroke, historically results in a lifetime of disability and chronic health complications from a sedentary lifestyle. ReWalk Robotics provides solutions that leverage robotics and biomechanics to facilitate physical a
Slide 5: A Leader in Neurological and Physical Rehabilitation
Strategic catalysts in 2023 FDA approval of stairs / curb capability Acquisition of AlterG Anti-Gravity Systems CMS approval for Medicare reimbursement of exoskeletons FDA submission of next-generation of exoskeleton Market-leading innovation – First-to-market personal exoskeleton for spinal cord in
Slide 6: A History of Innovation
A History of Innovation Confidential – ReWalk Robotics 2023 ReWalk Robotics has consistently pioneered the rehabilitation industry to establish novel solutions as standard of care First to: 2014 2015 2019 2020 2021 2022 2023 …establish exoskeleton SOP with the Dept. of Veterans Affairs …establish HC
Slide 7: NeuroRehabilitation Market is Sizeable and Growing
NeuroRehabilitation Market is Sizeable and Growing Confidential – ReWalk Robotics 2023 NeuroRehabilitation Equipment Market1 $ in billions CAGR of 8.3% NeuroRehabilitation Equipment Market by Product Type1 Neurorehabilitation: The rehabilitation and management of patients with diseases, injury, or d
Slide 8: Product Portfolio
Product Portfolio Confidential – ReWalk Robotics 2023 8
Slide 9: Portfolio of Solutions in Neurological and Physical Rehabilitation
Portfolio of Solutions in Neurological and Physical Rehabilitation Confidential – ReWalk Robotics 2023 ReWalk Personal Exoskeleton Cutting edge technology that provides paralyzed individuals with access to greater mobility and the health-related benefits of walking in daily life. ReStore Exo-Suit Ve
Slide 10: Flagship Product – ReWalk Personal Exoskeleton
Flagship Product – ReWalk Personal Exoskeleton Confidential – ReWalk Robotics 2023 Unprecedented freedom – Only personal exoskeleton enabling ambulatory access to real-world environments, including locations with stairs or curbs Natural gait – Only personal exoskeleton with six adjustable degrees of
Slide 11: Proven Health Benefits
Regular access to exoskeleton-assisted walking results in a multitude of health and wellness benefits for people with spinal cord injury2-8 Frequently reported benefits in literature include reductions in common comorbidities after SCI, including: Reduced spasticity Improved bowel/bladder function R
Slide 12: Increasing Progress of Reimbursement/Coverage
Confidential – ReWalk Robotics 2023 Germany 65M lives covered by DGUV (workers compensation) in Germany since 2019 Contractual coverage for 30% of all Germans through Statutory and Private health insurance plans 23.2M lives covered since 2020 Additional 2M covered lives added in 2021 2022 German Fed
Slide 13: SCI Market Potential to Be Determined by CMS Coverage
SCI Market Potential to Be Determined by CMS Coverage Confidential – ReWalk Robotics 2023 Eligible Candidates11,12 Reimbursement Pathway13,14 Potential Total Addressable Market Prevalence of SCI Survivors US 296,0009 Germany 74,00010 Global 7.1 Million10 US 15,416 Germany 2,064 Global 17,480 Potenti
Slide 14: Acquired Product – AlterG Anti-Gravity System
Expert & proven development – NASA-derived DAP technology to reduce the effects of gravity and allow people to move in new ways with finely calibrated support and reduced pain Established user base – Installed base of over 6,000 units at customers globally Highly synergistic – combined market presen
Slide 15: AlterG Market Potential
AlterG Market Potential Confidential – ReWalk Robotics 2023 Potential Total Addressable Market US 14,000 Germany 3,500 Global 40,000 Potential Global TAM $1.2B Inpatient Facilities Outpatient Clinics Professional & Elite Sports US 1,15215 44,00016 1,400 Germany 28817 11,00017 350 Global 3,50017 130,
Slide 16: Additional Product Lines
ReStore Exo-Suit for Stroke Rehabilitation Unique capabilities – only FDA and CE-cleared tool offering on-demand mechanical assistance to retrain post-stroke walking function during “push-off” (propulsion) Enhanced gait training – improves training specificity and intensity by promoting power and sy
Slide 17: Exo-Suit Stroke Market Potential
Exo-Suit Stroke Market Potential Confidential – ReWalk Robotics 2023 Stroke Rehabilitation Centers18 Direct Sales Presence In-Clinic Sales Inpatient Facilities Outpatient Clinics US 1,15215 44,00016 Germany 28817 11,00017 Global 3,50017 130,00017 Clinic Market 1,824 Potential Total Addressable Marke
Slide 18: MyoCycle FES Market Potential
MyoCycle FES Market Potential Confidential – ReWalk Robotics 2023 SCI Stroke MS US 296,00019 7M20 1.0M21 Personal (Home Use) Sales Medical Eligibility22 US Clinic Market 3,600 US Personal Market 13,200 Total 16,800 Potential Total Addressable Market NeuroRehab Focused Clinics26 ReWalk Dist. Rights23
Slide 19: Consolidation Strategy
Consolidation Strategy Confidential – ReWalk Robotics 2023 19
Slide 20: Consolidation Strategy Adds Scale and Supplements Growth
Enhancements to technology and features of ReWalk Exoskeleton Expansion of access through greater reimbursement coverage Internal development of new products Increasing penetration for distributed products Consolidation Strategy Adds Scale and Supplements Growth Confidential – ReWalk Robotics 2023 A
Slide 21: NeuroRehabilitation Market Attractive for Further Consolidation
Distribution of NeuroRehabilitation Technology Providers NeuroRehabilitation Market Attractive for Further Consolidation Confidential – ReWalk Robotics 2023 Fragmented industry with many small players Mostly private companies with limited access to capital Innovative technologies with distribution c
Slide 22: Transaction Summary
Transaction Summary Confidential – ReWalk Robotics 2023 A transformational step in our long-term strategy for growth from both our existing portfolio of products and from synergistic acquisitions
Slide 23: Key Attributes of Transaction
Significantly enhances ReWalk’s position as leader in innovative neurorehabilitation technologies that enable mobility and wellness Key Attributes of Transaction Confidential – ReWalk Robotics 2023 Strategy Adds novel technology – Differential Air Pressure – with proven commercial success and potent
Slide 24: Powerful and Complementary Combination
ReWalk Key Capabilities Powerful and Complementary Combination Confidential – ReWalk Robotics 2023 Field Sales for Home Use Marketing & Product Mgmt. Clinical / Training Regulatory / Quality Reimbursement / Access Operations / R&D Public Company Resources Creates a Formidable Platform for Consolidat
Slide 25: Perpetuating Cycle of Lead Generation
Perpetuating Cycle of Lead Generation Confidential – ReWalk Robotics 2023 Clinic Customers Individual Customers Traditional AlterG lead generation Traditional ReWalk lead generation AlterG System MyoCycle Pro ReStore Exo-Suit MyoCycle Home Clinic Network for Patient Training ReWalk Personal Exoskele
Slide 26: Deep and Talented Leadership Team
Deep and Talented Leadership Team Larry JasinskiChief Executive Officer Mike LawlessChief Financial Officer Charles RemsbergChief Sales Officer Miri ParienteVice President, Operations, Regulatory & Quality David Hexner Vice President, Research & Development Ami KraftExecutive Advisor to the CEO Almo
Slide 27: Financial Summary
Financial Summary Confidential – ReWalk Robotics 2023 $38 million* Cash & cash equivalents (as of June 30, 2023) Cash No debt Debt Path to profitability by 2026 with existing cash balance Cash Runway Well Positioned for Funding Internal Growth and Integration Strategy *Note: Estimated cash balance a
Slide 28: 2023 Milestones & Catalysts
2023 Milestones & Catalysts Confidential – ReWalk Robotics 2023 FDA clearance for use of our ReWalk Personal exoskeletons on stairs and curbs extends competitive advantage Predictable and simplified Medicare payment and claims processing system established for exoskeletons 510k submission for FDA
Slide 29: Well Positioned for Future Growth
Expanding addressable market in United States and Germany; first Medicare claims ongoing ReWalk Robotics Well Positioned for Future Growth Large, growing and fragmented Physical and Neurological Rehabilitation market with many attractive candidates for consolidation Fundamentally changes lives for i
Slide 30: Thank you!
NASDAQ:RWLK Thank you! Confidential – ReWalk Robotics 2023
Slide 31: References
1 Allied Health Neurorehabilitation Market Report: https://www.alliedmarketresearch.com/neurorehabilitation-market-A10461 2 Asselin et al., Arch Phys Med Rehab (2021) 3 Gorman et al., J Clin Med (2021) 4 Duddy et al., Sensors (2021) 5 Shackleton et al., J Rehab Med (2019) Juszczak et al., Topics Spi
Slide 32: References (continued)
15 MedPAC 2021 Report: www.medpac.gov/wp-content/uploads/2021/10/mar21_medpac_report_ch9_sec.pdf 16 www.ibisworld.com/industry-statistics/number-of-businesses/physical-therapy-rehabilitation-centers-united-states/ (accessed Jan 2023) 17 Estimates based on scaling US statistics for total German and G
ReWalk Robotics — Investor Presentation (October 2023) on 6ix